The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases.

As previously described, when examined individually, many of the secondary and other endpoints in this trial did not reach statistical significance primarily due to patient heterogeneity at baseline.

also in 111,027 other papers